Reporter brief
Dasatinib and Quercetin, a Combination of Senolytics to Treat Fibrotic Non-alcoholic Fatty Liver Disease - the TRUTH Study
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The actual efficacy of the intervention cannot be evaluated because effect size and outcomes are not reported
- Generalisability beyond the biopsy-proven NAFLD population studied is unclear
- Long-term durability or clinical relevance of any fibrosis reduction is not demonstrated
Study design and sample
Rct; Human.
Individuals with biopsy-proven NAFLD with fibrosis
- Design
- Rct
- Sample
- —
- Journal
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Published
- Apr 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.